ESMO 2025 | NUTRIGETNE: prediction tool for malnutrition and sarcopenia in GEP-NENs

So this is a Spanish study led by Maribel Del Olmo on behalf of the GETNE, the Spanish group focusing on NETs. The study is the first prospective multi-center observational study to assess the rate of malnutrition in patients with gastroenteropancreatic neuroendocrine tumors. Consider that so far we’ve got only a few retrospective studies focusing on malnutrition in these kinds of patients. It is quite striking to see the results of the study that finds approximately 60% of patients who were malnourished. If we try to put this into context, this figure seems a little bit on the higher side. For example, if you compare with available literature on pancreatic adenocarcinoma or esophageal cancer or stomach cancer, which are cancers that are commonly associated with malnutrition, the figure in gastroenteropancreatic NETs seems to be a little bit higher than in these malignancies, and this is quite well, this needs further investigation in my opinion, and my comment on this would be that you know, like if you want to find something, then at the end you will find it. The study is very important because it finds, you know, like several predictors of malnutrition, and in particular, the authors come up with a nomogram that can be used in daily clinical practice. Are we going to use this nomogram in daily clinical practice? Personally, I doubt it. But, you know, like science-wise, this is important because the main question, in my opinion, is how can we treat malnourished patients with GEP-NETs? And in this regard, two main points: first, nutritional interventions; second, exercise. But, you know, like this nomogram can help us stratify patients that need those interventions.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.